Characteristics of Membranoproliferative Glomerulonephritis Based on a New Classification at a Single Center

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2019 Mar 12

PMID 30854618

Citations 4

Authors

Marie Nakano

Kazunori Karasawa

Takahito Moriyama

Keiko Uchida

Kosaku Nitta

Affiliations

Soon will be listed here.

Abstract

Background: Recently, a new classification has been established for membranoproliferative glomerulonephritis (MPGN). However, the effect of the new classification on MPGN treatment is not fully understood.

Methods: We conducted a retrospective study of 87 patients with biopsies diagnosed as MPGN. We reclassified 87 MPGN patients diagnosed between 1977 and 2014 at our hospital, according to the new classification, and analyzed both primary immune complex (IC)- and Alternative pathway (AP)-mediated MPGN [corrected] in terms of clinicopathological features, treatment, and renal prognosis.

Results: Proteinuria was abundant in the IC-mediated MPGN group (p = 0.0063), and the serum albumin level was significantly lower in the IC-mediated MPGN group (p = 0.0186). The serum C3 value was significantly lower in the CP-mediated MPGN group (p = 0.0317). Serum CH50 values were also lower in the CP-mediated MPGN group (p = 0.0404). However, glomerular deposition of C3 showed no significant differences in immunofluorescence findings. The 148.6-month renal survival rate was similar in both groups (p = 0.445).

Conclusion: These results suggested no significant differences in complement activation of the solid phase in local glomeruli and therefore equivalent in renal prognosis [corrected].

Citing Articles

Short-term renal and patient outcomes of primary immunoglobulin-associated mesangiocapillary glomerulonephritis: Insights from a developing country.

Elahi T, Ahmed S, Mubarak M World J Nephrol. 2024; 13(4):98969.

PMID: 39723356 PMC: 11572649. DOI: 10.5527/wjn.v13.i4.98969.

Clinicopathological characteristics and outcomes of adult patients with idiopathic membranoproliferative glomerulonephritis according to an immunofluorescence-based classification.

Elahi T, Ahmed S, Ahmed E, Mubarak M J Nephrol. 2024; 37(8):2255-2265.

PMID: 39400860 DOI: 10.1007/s40620-024-02083-7.

Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children.

Xu L, Wei F, Feng J, Liu J, Liu J, Tang X Transl Pediatr. 2022; 10(11):2985-2996.

PMID: 34976764 PMC: 8649586. DOI: 10.21037/tp-21-286.

Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

Nakagawa N, Mizuno M, Kato S, Maruyama S, Sato H, Nakaya I PLoS One. 2021; 16(9):e0257397.

PMID: 34520493 PMC: 8439563. DOI: 10.1371/journal.pone.0257397.

References

Cook H, Pickering M . Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury. J Am Soc Nephrol. 2017; 29(1):9-12. PMC: 5748929. DOI: 10.1681/ASN.2017111183. View

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C . Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol. 2017; 29(1):283-294. PMC: 5748907. DOI: 10.1681/ASN.2017030258. View

Sethi S, Nester C, Smith R . Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2011; 81(5):434-41. PMC: 4428602. DOI: 10.1038/ki.2011.399. View

Zhang Y, Nester C, Martin B, Skjoedt M, Meyer N, Shao D . Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol. 2014; 9(11):1876-82. PMC: 4220750. DOI: 10.2215/CJN.01820214. View

Ito N, Ohashi R, Nagata M . C3 glomerulopathy and current dilemmas. Clin Exp Nephrol. 2016; 21(4):541-551. PMC: 5721121. DOI: 10.1007/s10157-016-1358-5. View

Fervenza F, Sethi S, Glassock R . Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrol Dial Transplant. 2012; 27(12):4288-94. DOI: 10.1093/ndt/gfs288. View

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E . Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016; 71:131-142. DOI: 10.1016/j.molimm.2016.01.010. View

Mizuno M, Suzuki Y, Ito Y . Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clin Exp Nephrol. 2017; 22(1):3-14. DOI: 10.1007/s10157-017-1405-x. View

Masani N, Jhaveri K, Fishbane S . Update on membranoproliferative GN. Clin J Am Soc Nephrol. 2014; 9(3):600-8. PMC: 3944764. DOI: 10.2215/CJN.06410613. View

10.

Bomback A, Santoriello D, Avasare R, Regunathan-Shenk R, Canetta P, Ahn W . C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018; 93(4):977-985. DOI: 10.1016/j.kint.2017.10.022. View

11.

Clynes R, Dumitru C, Ravetch J . Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998; 279(5353):1052-4. DOI: 10.1126/science.279.5353.1052. View

12.

Mathern D, Heeger P . Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol. 2015; 10(9):1636-50. PMC: 4559511. DOI: 10.2215/CJN.06230614. View

13.

Levin A . Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999; 70:S41-6. DOI: 10.1046/j.1523-1755.1999.07006.x. View

14.

Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E . Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994; 67(1):59-65. DOI: 10.1159/000187889. View

15.

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012; 366(12):1119-31. DOI: 10.1056/NEJMra1108178. View

16.

Hou J, Markowitz G, Bomback A, Appel G, Herlitz L, Stokes M . Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2013; 85(2):450-6. DOI: 10.1038/ki.2013.340. View

17.

Herlitz L, Bomback A, Markowitz G, Stokes M, Smith R, Colvin R . Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012; 23(7):1229-37. PMC: 3380652. DOI: 10.1681/ASN.2011121186. View

18.

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011; 31(4):341-8. DOI: 10.1016/j.semnephrol.2011.06.005. View

19.

Takei T, Itabashi M, Moriyama T, Shimizu A, Tsuruta Y, Ochi A . Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis. Clin Exp Nephrol. 2012; 17(1):92-8. DOI: 10.1007/s10157-012-0667-6. View

20.

Bomback A, Appel G . Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012; 8(11):634-42. DOI: 10.1038/nrneph.2012.213. View